Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$3.19 USD
-0.02 (-0.62%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.18 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARA 3.19 -0.02(-0.62%)
Will TARA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARA
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
TARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TARA
Is TARA ready to move higher? 20 Day Moving Average Support shows up after sliding 0.62%
Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
Crossed Above 20 Day Moving Average appears for TARA after 5.94% move
Stochastic Reached Oversold appears for TARA after 1.3% move
Citizens JMP healthcare analysts hold an analyst/industry conference call